Tema ETFs LLC Invests $1.03 Million in Kura Oncology, Inc. $KURA

Tema ETFs LLC bought a new stake in Kura Oncology, Inc. (NASDAQ:KURA) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 93,761 shares of the company’s stock, valued at approximately $1,029,000. Tema ETFs LLC owned approximately 0.11% of Kura Oncology as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of KURA. Suvretta Capital Management LLC increased its holdings in Kura Oncology by 5.7% in the fourth quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock valued at $89,099,000 after buying an additional 459,422 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Kura Oncology by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock worth $57,224,000 after buying an additional 39,105 shares during the last quarter. Armistice Capital LLC lifted its holdings in Kura Oncology by 5.7% during the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after buying an additional 264,000 shares during the last quarter. State Street Corp grew its position in shares of Kura Oncology by 47.5% in the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after acquiring an additional 1,587,959 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in shares of Kura Oncology by 36.6% in the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after acquiring an additional 820,020 shares in the last quarter.

Kura Oncology Trading Up 1.5%

Shares of NASDAQ KURA opened at $10.09 on Friday. The company has a market cap of $895.69 million, a price-to-earnings ratio of -2.99 and a beta of 0.38. Kura Oncology, Inc. has a 12-month low of $6.35 and a 12-month high of $12.49. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. The stock’s 50 day simple moving average is $10.17 and its 200 day simple moving average is $9.32.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 169.73% and a negative net margin of 384.30%.The firm had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Equities research analysts expect that Kura Oncology, Inc. will post -3.45 EPS for the current year.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Quarterly results beat expectations: Kura reported a second-quarter loss of $0.77 per share, narrower than the consensus estimate of a $0.88 loss. Revenue of $20.87 million also exceeded the $20.16 million analyst forecast. Kura Oncology Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: KOMZIFTI sales grew strongly: Ziftomenib generated $9.1 million in net product revenue, up 57% from the first quarter, while new patient starts increased 35% to approximately 115. The commercial ramp provides an important source of near-term revenue growth. Kura Oncology Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst confidence increased: Wedbush raised its Kura price target from $36 to $38 and assigned an “outperform” rating. The target implies substantial upside from the stock’s recent level, supporting the positive trading reaction. Wedbush Raises Kura Oncology Price Target
• Neutral Sentiment: Future milestones remain ahead: Management outlined potential collaboration revenue of $90 million to $110 million in 2027 and is targeting topline results from the KOMET-017 study in 2028. These milestones could materially affect valuation, but they remain dependent on execution and clinical outcomes. Kura Outlines 2027 Collaboration Revenue and 2028 Trial Timeline
• Negative Sentiment: Kura remains loss-making: The company’s quarterly loss increased from $0.75 per share a year earlier, and it continues to report deeply negative margins and returns on equity. Sustained commercialization costs and dependence on future clinical success remain key risks. Kura Oncology Earnings Results and Conference Call

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Sanford C. Bernstein set a $24.00 price target on Kura Oncology in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Wells Fargo & Company set a $24.00 target price on shares of Kura Oncology in a report on Thursday, June 4th. Finally, Jefferies Financial Group set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, May 28th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.62.

Insider Activity

In other news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the transaction, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 7.60% of the company’s stock.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.